Use of the quorum-sensing inhibitor RNAIII-inhibiting peptide to prevent biofilm formation in vivo by drug-resistant Staphylococcus epidermidis

Journal of Infectious Diseases

Volumn 187, Issue 4, 2003, Pages 625-630

  Balaban, Naomi ^a,b   Giacometti, Andrea ^c,e   Cirioni, Oscar ^c   Gov, Yael ^a   Ghiselli, Roberto ^c   Mocchegiani, Federico ^c   Viticchi, Claudio ^c   Del Prete, Maria Simona ^c   Saba, Vittorio ^c   Scalise, Giorgio ^c   Dell'Acqua, Giorgio ^d  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d Arval Biological Laboratories   (Switzerland)

^e c/o Ospedale Regionale ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFAZOLIN; DALFOPRISTIN PLUS QUINUPRISTIN; IMIPENEM; LEVOFLOXACIN; PSEUDOMONIC ACID; RIFAMPICIN; RNAIII INHIBITING PEPTIDE; SYNTHETIC PEPTIDE; TEICOPLANIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ARTICLE; BIOFILM; CELL COMMUNICATION; CONTROLLED STUDY; DEVICE INFECTION; DRUG EFFICACY; DRUG POTENTIATION; FOREIGN BODY; GRAFT INFECTION; HUMAN; HUMAN CELL; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; RAT; STAPHYLOCOCCUS EPIDERMIDIS; STAPHYLOCOCCUS INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL ADHESION; BACTERIAL PROTEINS; BIOFILMS; CELL LINE; DRUG RESISTANCE; HUMANS; MALE; OLIGOPEPTIDES; PHOSPHOPROTEINS; PHOSPHORYLATION; RATS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS;

EID: 0037442494     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/345879     Document Type: Article

References (30)

1. Huebner J, Goldman DA. Coagulase-negative staphylococci: role as pathogens. Annu Rev Med 1999; 50:223-36.
2. Schierholz JM, Beuth J. Implant infections: a haven for opportunistic bacteria. J Hosp Infect 2001; 49:87-93.
3. Stewart PS, Costerton JW. Antibiotic resistance in biofilms. Lancet 2001; 358:135-8.
4. Linnola R. Staphylococcus epidermidis and intraocular lenses. Ophthalmology 2001; 108:1518-9.
5. Barie PS. Antibiotic-resistant gram-positive cocci: implications for surgical practice. World J Surg 1998; 22:118-26.
6. Henke PK, Bergamini TM, Rose SM, Richardson JD. Current options in prosthetic vascular graft infection. Am Surg 1998; 64:39-45.
7. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284:1318-22.
8. Mah TF, O'Toole GA. Mechanism of biofilm resistance to antimicrobial agents. Trends Microbiol 2001; 9:34-9.
9. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999; 37:1771-6.
10. Daschner FD, Kropec A. Glycopeptides in the treatment of staphylococcal infections. Eur J Clin Microbiol Infect Dis 1995; 14:S12-7.
11. Carbon C. MRSA and MRSE: is there an answer? Clin Microbiol Infect 2000; 6(Suppl 2):17-22.
12. Raad I, Alrahwan A, Roltson K. Staphylococcus epidermidis: emerging resistance and need for alternative agents. Clin Infect Dis 1998; 26:1182-7.
13. Biavasco F, Vignaroli C, Varaldo PE. Glycopeptide resistance in coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis 2000; 19:403-17.
14. Cercenado E, Garcia-Leoni ME, Diaz MD, et al. Emergence of teicoplanin-resistant coagulase-negative staphylococci. J Clin Microbiol 1996; 34:1765-8.
15. Tiller JC, Liao CJ, Lewis K, Klibanov AM. Designing surfaces that kill bacteria on contact. Proc Natl Acad Sci USA 2001; 98:5981-5.
16. Gottenbos B, Grijpma DW, van der Mei HC, Feijen J, Busscher HJ. Antimicrobial effects of positively charged surfaces on adhering gram-positive and gram-negative bacteria. J Antimicrob Chemother 2001; 48:7-13.
17. Shirtliff M, Mader J, Camper A. Molecular interactions in biofilms. Chem Biol 2002; 9:859-71.
18. Vuong C, Otto M. Staphylococcus epidermidis infections. Microbes Infect 2002; 4:481-9.
19. Miller MB, Bassler BL. Quorum sensing in bacteria. Annu Rev Microbiol 2001; 55:165-99.
20. Balaban N, Goldkorn T, Nhan RT, et al. Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus. Science 1998; 280:438-40.
21. Balaban N, Collins LV, Cullor JS, et al. Prevention of diseases caused by Staphylococcus aureus using the peptide RIP. Peptides 2000; 21:1301-11.
22. Balaban N, Goldkorn T, Gov Y, et al. Regulation of Staphylococcus aureus pathogenesis via target of RNAIII-activating protein (TRAP). J Biol Chem 2001; 276:2658-67.
23. Gov Y, Bitler A, Dell'Acqua G, Tortes JV, Balaban N. RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis. Peptides 2001; 22:1609-20.
24. Balaban N, Gov Y, Bitler A, Boelaert JR. Prevention of Staphylococcus aureus biofilm on dialysis catheters and adherence to human cells. Kidney Int 2003; 63:340-5.
25. Vieira-da-Motta O, Damasceno Ribeiro P, Dias da Silva W, Medina-Acosta E. RIP inhibits agr-regulated toxin production. Peptides 2001; 22:1621-7.
26. Van Wamel WJ, van Rossum G, Verhoef J, Vandenbroucke-Grauls CM, Fluit AC. Cloning and characterization of an accessory gene regulator (agr)-like focus from Staphylococcus epidermidis. FEMS Microbiol Lett 1998; 163:1-9.
27. Giacometti A, Cirioni O, Ghiselli R, et al. Mupirocin prophylaxis against methicillin-susceptible, methicillin-resistant, or vancomycin-intermediate Staphylococcus epidermidis vascular-graft infection. Antimicrob Agents Chemother 2000; 44:2842-4.
28. Giacometti A, Cirioni O, Ghiselli R, et al. Efficacy of polycationic peptides in preventing vascular graft infection due to Staphylococcus epidermidis. J Antimicrob Chemother 2000; 46:751-6.
29. Ghiselli R, Giacometti A, Goffi L, et al. Efficacy of rifampin-levofloxacin as a prophylactic agent in preventing Staphylococcus epidermidis graft infection. Eur J Vasc Endovasc Surg 2000; 20:508-11.
30. Paradisi F, Corti G, Messeri D. Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am 2001; 85:1-17.